# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Tharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.
Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developi...
Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug...
Tharimmune achieves success in Phase 1 trial for TH104, a buccal film with nalmefene. Encouraging safety profile and potential ...
Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous...